Comparative Pharmacology
Head-to-head clinical analysis: GENCEPT 10 11 21 versus YASMIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENCEPT 10 11 21 versus YASMIN.
GENCEPT 10/11-21 vs YASMIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GENCEPT 10/11-21 is a combination contraceptive vaginal ring containing ethinyl estradiol and etonogestrel. Ethinyl estradiol is an estrogen that suppresses gonadotropin release, inhibiting ovulation. Etonogestrel is a progestin that thickens cervical mucus, inhibiting sperm penetration, and alters the endometrium.
Combination of ethinyl estradiol and drospirenone suppresses gonadotropins, inhibiting ovulation. Drospirenone has antimineralocorticoid activity, reducing water retention, and antiandrogenic activity.
One tablet (10 mg ethinyl estradiol and 11 mg gestodene on days 1-7, then placebo on days 8-21) orally once daily for 21 days, followed by 7 placebo days.
One tablet (ethinyl estradiol 0.03 mg / drospirenone 3 mg) orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Terminal elimination half-life is 24-30 hours; allows once-daily dosing; steady-state achieved in 5-7 days
Terminal elimination half-life is approximately 30 hours for drospirenone; steady-state concentration is achieved after 10 days of daily dosing.
Renal (30-40% as unchanged drug and metabolites), biliary/fecal (50-60% as metabolites)
Approximately 40% renal and 60% fecal after oral administration; metabolites are excreted as glucuronide and sulfate conjugates.
Category C
Category C
Oral Contraceptive
Oral Contraceptive